Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer

Cancer

Volumn 119, Issue 19, 2013, Pages 3446-3453

  Daskivich, Timothy J ^a,b   Chamie, Karim ^a   Kwan, Lorna ^a   Dash, Atreya ^c,d   Greenfield, Sheldon ^e   Litwin, Mark S ^a,b,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

comorbidity; outcome assessment; prostate; prostatic neoplasms; survival

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT;

COMORBIDITY; OUTCOME ASSESSMENT; PROSTATE; PROSTATIC NEOPLASMS; SURVIVAL;

AGED; AGED, 80 AND OVER; COMORBIDITY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84884908099     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28226     Document Type: Article

References (29)

1. Montie JE, Smith JA,. Whitmoreisms: memorable quotes from Willet F. Whitmore, Jr, M.D. Urology. 2004; 63: 207-209.
2. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
3. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010; 28: 126-131.
4. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008; 112: 2664-2670.
5. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012; 61: 1096-1106.
6. Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008; 53: 950-959.
7. Inman BA, Davies JD, Rangel LJ, et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level ≥ 50 ng/mL. J Urol. 2008; 113: 1544-1551.
8. Daskivich TJ, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011; 117: 2058-2066.
9. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302: 1202-1209.
10. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 4448-4456.
11. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007; 110: 1493-1500.
12. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99: 1516-1524.
13. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010; 60: 194-201.
14. Nanda A, Chen M-H, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009; 302: 866-873.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
16. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974.
17. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML,. Mayo Clinic validation of the D' amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008; 179: 1354-1360.
18. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
19. Daskivich TJ, Chamie K, Kwan L, et al. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer. 2011; 117: 4642-4650.
20. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL,. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011; 29: 1335-1341.
21. Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M,. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011; 18: 833-839.
22. Tewari A, Johnson CC, Divine G, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol. 2004; 171: 1513-1519.
23. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS,. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009; 101: 888-892.
24. Loeb S, Schaeffer EM, Trock BJ, et al. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 2010; 76: 710-714.
25. Spahn M, Weiss C, Bader P, et al. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation. Urol Int. 2010; 84: 164-173.
26. Koupparis AJ, Grummet JP, Hurtado-Coll A, et al. Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. Can Urol Assoc J. 2011; 5: E156-E161.
27. Cooperberg MR, Vickers AJ, Broering JM, et al. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010; 116: 5226-5234.
28. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011; 364: 1708-1717.
29. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367: 203-213.